DSGN shows significant financial deterioration with net losses widening 41% to $69.8M, R&D expenses surging 33%, and cash declining 25% to $16.9M amid expanded clinical development.
The company's burn rate has accelerated substantially with operating cash outflows increasing 26% to $54.4M annually, creating potential liquidity concerns given the declining cash position. While the expansion from two to three clinical programs explains higher R&D spending, the widening losses and cash consumption trajectory raises questions about runway and potential future financing needs.
DSGN's financials reflect an aggressive R&D expansion phase with expenses growing 33% to $59.1M while losses deepened 41% to $69.8M. Cash reserves declined 25% to $16.9M while current liabilities surged 54% to $13.1M, indicating accelerated cash burn and potential near-term financing pressures. The combination of widening losses, declining cash, and rising liabilities suggests the company may need to secure additional funding within the next 12-18 months to sustain operations.
Current liabilities surged 54.3% — significant near-term obligations; verify ability to meet short-term debt.
Capex reduced 43.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Net income declined 40.7% — review whether driven by operations, interest costs, or non-recurring items.
Liabilities grew 37.1% — significant increase in debt or obligations, assess impact on financial flexibility.
R&D investment increased 33.3% — signals commitment to future product development, though near-term margin impact.
Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
Cash decreased 25.3% — monitor burn rate and upcoming capital needs.
Equity decreased 12.2% — buybacks or losses reducing book value, monitor solvency ratios.
Total assets contracted 10.3% — asset sales, write-downs, or balance sheet optimization underway.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →